Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 2/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
| ▸ | F12 | P00748 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16756982 | 0.84 | F2 (0.51) | RAB9AKMT2ANPC1SMN1; SMN2PKM | |
| SCHEMBL17541934 | 0.82 | PLA2G7 (0.46) | TSHRKMT2AMEN1SMN1; SMN2HPGD | |
| SCHEMBL10679054 | 0.80 | LMNA (0.38) | TSHRLMNAMAPT | |
| SCHEMBL5983023 | 0.80 | KMT2A (0.55) | RAB9AKMT2ANPC1MEN1SMN1; SMN2 | |
| SCHEMBL1387674 | 0.78 | L3MBTL1 (0.47) | RAB9AL3MBTL1TSHRKMT2ANPC1 | |
| SCHEMBL27819780 | 0.77 | PARP1 (0.43) | LMNAMAPT | |
| SCHEMBL5694141 | 0.75 | DYRK1A (0.47) | RAB9AL3MBTL1TSHRKMT2ANPC1 | |
| SCHEMBL21186 | 0.75 | NOTUM (0.43) | LMNAMAPTGSK3A | |
| SCHEMBL10348675 | 0.75 | MEN1 (0.57) | RAB9AL3MBTL1TSHRKMT2ANPC1 | |
| SCHEMBL10348640 | 0.75 | RAB9A (0.46) | RAB9AL3MBTL1TSHRNPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 960 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260103737-A1 | ENZYMATIC METHODS TO GENERATE HIGH YIELDS OF SEQUENCE SPECIFIC RNA OLIGONUCLEOTIDES WITH EXTREME PRECISION | UNIV MASSACHUSETTS (US) | 2026-04-16 | — | — | US | claimed |
| US-11987599-B2 | Solid support for synthesizing nucleic acid sequences and methods for making and using | UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-05-21 | — | — | US | claimed |
| US-20230271998-A1 | SOLID SUPPORT FOR SYNTHESIZING NUCLEIC ACID SEQUENCES AND METHODS FOR MAKING AND USING | UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-08-31 | — | — | US | claimed |
| US-20220195497-A1 | HYBRIDIZING all-LNA OLIGONUCLEOTIDES | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2022-06-23 | — | — | US | claimed |
| EP-3980554-A1 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | F. Hoffmann-La Roche AG (CH) | 2022-04-13 | — | — | EP | claimed |
| WO-2022005988-A2 | SOLID SUPPORT FOR SYNTHESIZING NUCLEIC ACID SEQUENCES AND METHODS FOR MAKING AND USING | UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-01-06 | — | — | WO | claimed |
| WO-2020245377-A1 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2020-12-10 | — | — | WO | claimed |
| CN-108409818-B | Method for synthesizing cytosine nucleoside | 新乡拓新药业股份有限公司 | 2020-09-11 | — | — | CN | claimed |
| EP-3004131-B1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | AM CHEMICALS LLC (US) | 2020-07-22 | — | — | EP | claimed |
| CN-106905398-B | Synthetic method of sofosbuvir | ZHEJIANG A & F UNIVERSITY (CN) | 2019-12-10 | — | — | CN | claimed |
| EP-0570514-A4 | METHYLENE PHOSPHONATE NUCLEOSIDE ANALOGS AND OLIGONUCLEOTIDE ANALOGS MADE THEREFROM | GILEAD SCIENCES INC (US) | 1994-08-17 | — | — | EP | claimed |
| WO-1994015622-A1 | NUCLEOSIDE DERIVATIVES AND THEIR USE AS EXCITATORY AMINO ACID ANTAGONISTS | CAMBRIDGE NEUROSCIENCE (US) | 1994-07-21 | — | — | WO | claimed |
| WO-1994001445-A1 | BASE-PROTECTED NUCLEOTIDE ANALOGS WITH PROTECTED THIOL GROUPS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1994-01-20 | — | — | WO | claimed |
| EP-0574386-A1 | NOVEL PROCESS FOR THE PREPARATION OF NUCLEOTIDES | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 1993-12-22 | — | — | EP | claimed |
| EP-0570514-A1 | METHYLENE PHOSPHONATE NUCLEOSIDE ANALOGS AND OLIGONUCLEOTIDE ANALOGS MADE THEREFROM | GILEAD SCIENCES, INC. (US) | 1993-11-24 | — | — | EP | claimed |
| EP-0574386-A4 | NOVEL PROCESS FOR THE PREPARATION OF NUCLEOTIDES. | BRISTOL MYERS SQUIBB CO (US) | 1993-10-27 | — | — | EP | claimed |
| WO-1992013869-A1 | METHYLENE PHOSPHONATE NUCLEOSIDE ANALOGS AND OLIGONUCLEOTIDE ANALOGS MADE THEREFROM | GILEAD SCIENCES, INC. (US) | 1992-08-20 | — | — | WO | claimed |
| WO-1992002511-A1 | NOVEL PROCESS FOR THE PREPARATION OF NUCLEOTIDES | BRISTOL-MYERS SQUIBB COMPANY (US) | 1992-02-20 | — | — | WO | claimed |
| EP-0121112-B1 | 2'-DEOXY-3-PHOSPHONYLMETHYL NUCLEOSIDES AND METHOD FOR THEIR PREPARATION | Gesellschaft für Biotechnologische Forschung mbH (GBF) (DE) | 1987-05-13 | — | — | EP | claimed |
| EP-0121112-A1 | 2'-Deoxy-3-phosphonylmethyl nucleosides and method for their preparation | Gesellschaft für Biotechnologische Forschung mbH (GBF) (DE) | 1984-10-10 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260103737-A1 | ENZYMATIC METHODS TO GENERATE HIGH YIELDS OF SEQUENCE SPECIFIC RNA OLIGONUCLEOTIDES WITH EXTREME PRECISION | RNGTT, POLRMT, POLM | RAB9A 4388/4885L3MBTL1 191/4885TSHR 1953/4885 |
| US-11987599-B2 | Solid support for synthesizing nucleic acid sequences and methods for making and using | RNGTT, NSUN2, POLN | RAB9A 3828/4885L3MBTL1 950/4885TSHR 3625/4885 |
| US-20230271998-A1 | SOLID SUPPORT FOR SYNTHESIZING NUCLEIC ACID SEQUENCES AND METHODS FOR MAKING AND USING | RNGTT, NSUN2, POLN | RAB9A 3828/4885L3MBTL1 950/4885TSHR 3625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.